Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Make a Passover gift and support Jewish journalism. DONATE NOW
Fast Forward

Teva Chief Jeremy Levin Quits Abruptly

Teva Pharmaceutical Industries announced Wednesday that its president and CEO for the past two years, Jeremy Levin, has agreed to step down.

The company, which is the world’s largest manufacturer of generic drugs, said that on an interim basis, the top spot would be filled by Eyal Desheh, Teva’s executive vice president and chief financial officer.

Just days before, Levin had denied a report by Channel 2 that he was considering resigning. Trading in shares of Teva were halted following the announcement of Levin’s departure.

“Since I joined Teva, we have made tremendous progress in setting a new course for the company,” Levin said following his resignation. “I wish the company and its people, who I respect greatly, every success. I look forward to pursuing new opportunities where I can continue to apply my experience and contribute to the evolution of the global pharmaceutical industry.”

Levin’s departure follows a rift between company management and its board following public criticism of Teva for plans to lay off 5,000 worldwide and over tax incentives the firm received in Israel.

For more go to Haaretz

This is a moment of great uncertainty. Here’s what you can do about it.

This is a moment of great uncertainty for the news media, for the Jewish people, and for our sacred democracy. It is a time of confusion and declining trust in public institutions. An era in which we need humans to report facts, conduct investigations that hold power to account, tell stories that matter and share honest discourse on all that divides us.

With no paywall or subscriptions, the Forward is entirely supported by readers like you. Every dollar you give this Passover is invested in the future of the Forward — and telling the American Jewish story fully and fairly.

The Forward doesn’t rely on funding from institutions like governments or your local Jewish federation. There are thousands of readers like you who give us $18 or $36 or $100 each month or year.

Support our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:

  • Credit the Forward
  • Retain our pixel
  • Preserve our canonical link in Google search
  • Add a noindex tag in Google search

See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.